LiverPRO Reduces False Positives and Screening Costs Compared With Fibrosis-4 Index in Steatotic Liver Disease.

Targeted screening for steatotic liver disease (SLD) is cost-effective and encourages lifestyle changes.1-3 The European Association for the Study of the Liver (EASL) recommends screening adults at risk of SLD to enable timely diagnosis and prevention, especially with emerging treatments like resmetirom and semaglutide.4 EASL guidelines suggest the fibrosis-4 index (FIB-4) as the first-line noninvasive test to identify candidates for secondary care referral with more accurate, resource-intensive assessments like liver stiffness measurements by transient elastography (TE).4.